The Experts below are selected from a list of 4359 Experts worldwide ranked by ideXlab platform

Wanwisa Dejnirattisai - One of the best experts on this subject based on the ideXlab platform.

  • a protective zika virus e dimer based subunit vaccine engineered to abrogate Antibody Dependent Enhancement of dengue infection
    Nature Immunology, 2019
    Co-Authors: Jose Sloncampos, Wanwisa Dejnirattisai, Wiyada Wongwiwat, Bw Jagger, La Durnell, Cesar Lopezcamacho, Emma S Winkler, Rita E Chen, Arturo Reyessandoval
    Abstract:

    Infections with dengue virus (DENV) and Zika virus (ZIKV) can induce cross-reactive Antibody responses. Two immunodominant epitopes-one to precursor membrane protein and one to the fusion loop epitope on envelope (E) protein-are recognized by cross-reactive antibodies1-3 that are not only poorly neutralizing, but can also promote increased viral replication and disease severity via Fcγ receptor-mediated infection of myeloid cells-a process termed Antibody-Dependent Enhancement (ADE)1,4,5. ADE is a significant concern for both ZIKV and DENV vaccines as the induction of poorly neutralizing cross-reactive antibodies may prime an individual for ADE on natural infection. In this report, we describe the design and production of covalently stabilized ZIKV E dimers, which lack precursor membrane protein and do not expose the immunodominant fusion loop epitope. Immunization of mice with ZIKV E dimers induces dimer-specific antibodies, which protect against ZIKV challenge during pregnancy. Importantly, the ZIKV E-dimer-induced response does not cross-react with DENV or induce ADE of DENV infection.

  • dengue virus sero cross reactivity drives Antibody Dependent Enhancement of infection with zika virus
    Nature Immunology, 2016
    Co-Authors: Wanwisa Dejnirattisai, Giovanna Barbaspaeth, Alexander Rouvinski, Anavaj Sakuntabhai, Thaneeya Duangchinda, Piyada Supasa, Wiyada Wongwiwat, Vanmai Caolormeau
    Abstract:

    Zika virus (ZIKV) was discovered in 1947 and was thought to lead to relatively mild disease. The recent explosive outbreak of ZIKV in South America has led to widespread concern, with reports of neurological sequelae ranging from Guillain Barre syndrome to microcephaly. ZIKV infection has occurred in areas previously exposed to dengue virus (DENV), a flavivirus closely related to ZIKV. Here we investigated the serological cross-reaction between the two viruses. Plasma immune to DENV showed substantial cross-reaction to ZIKV and was able to drive Antibody-Dependent Enhancement (ADE) of ZIKV infection. Using a panel of human monoclonal antibodies (mAbs) to DENV, we showed that most antibodies that reacted to DENV envelope protein also reacted to ZIKV. Antibodies to linear epitopes, including the immunodominant fusion-loop epitope, were able to bind ZIKV but were unable to neutralize the virus and instead promoted ADE. Our data indicate that immunity to DENV might drive greater ZIKV replication and have clear implications for disease pathogenesis and future vaccine programs for ZIKV and DENV.

  • dengue virus sero cross reactivity drives Antibody Dependent Enhancement of infection with zika virus
    Nature Immunology, 2016
    Co-Authors: Wanwisa Dejnirattisai, Giovanna Barbaspaeth, Alexander Rouvinski, Anavaj Sakuntabhai, Thaneeya Duangchinda, Piyada Supasa, Wiyada Wongwiwat, Vanmai Caolormeau
    Abstract:

    Infection with Zika virus has occurred in areas previously exposed to dengue virus, a closely related flavivirus. Screaton and colleagues find that monoclonal antibodies to dengue virus cross-react with Zika virus and enhance infection.

  • Cross-Reacting Antibodies Enhance Dengue Virus Infection in Humans
    Science, 2010
    Co-Authors: Wanwisa Dejnirattisai, Amonrat Jumnainsong, Naruthai Onsirisakul, Patricia Fitton, Sirijitt Vasanawathana, Wannee Limpitikul, Chunya Puttikhunt, Carolyn Edwards, Thaneeya Duangchinda, Sunpetchuda Supasa
    Abstract:

    Dengue virus co-circulates as four serotypes, and sequential infections with more than one serotype are common. One hypothesis for the increased severity seen in secondary infections is Antibody-Dependent Enhancement (ADE) leading to increased replication in Fc receptor–bearing cells. In this study, we have generated a panel of human monoclonal antibodies to dengue virus. Antibodies to the structural precursor-membrane protein (prM) form a major component of the response. These antibodies are highly cross-reactive among the dengue virus serotypes and, even at high concentrations, do not neutralize infection but potently promote ADE. We propose that the partial cleavage of prM from the viral surface reduces the density of antigen available for viral neutralization, leaving dengue viruses susceptible to ADE by Antibody to prM, a finding that has implications for future vaccine design.

Vanmai Caolormeau - One of the best experts on this subject based on the ideXlab platform.

  • dengue virus sero cross reactivity drives Antibody Dependent Enhancement of infection with zika virus
    Nature Immunology, 2016
    Co-Authors: Wanwisa Dejnirattisai, Giovanna Barbaspaeth, Alexander Rouvinski, Anavaj Sakuntabhai, Thaneeya Duangchinda, Piyada Supasa, Wiyada Wongwiwat, Vanmai Caolormeau
    Abstract:

    Infection with Zika virus has occurred in areas previously exposed to dengue virus, a closely related flavivirus. Screaton and colleagues find that monoclonal antibodies to dengue virus cross-react with Zika virus and enhance infection.

  • dengue virus sero cross reactivity drives Antibody Dependent Enhancement of infection with zika virus
    Nature Immunology, 2016
    Co-Authors: Wanwisa Dejnirattisai, Giovanna Barbaspaeth, Alexander Rouvinski, Anavaj Sakuntabhai, Thaneeya Duangchinda, Piyada Supasa, Wiyada Wongwiwat, Vanmai Caolormeau
    Abstract:

    Zika virus (ZIKV) was discovered in 1947 and was thought to lead to relatively mild disease. The recent explosive outbreak of ZIKV in South America has led to widespread concern, with reports of neurological sequelae ranging from Guillain Barre syndrome to microcephaly. ZIKV infection has occurred in areas previously exposed to dengue virus (DENV), a flavivirus closely related to ZIKV. Here we investigated the serological cross-reaction between the two viruses. Plasma immune to DENV showed substantial cross-reaction to ZIKV and was able to drive Antibody-Dependent Enhancement (ADE) of ZIKV infection. Using a panel of human monoclonal antibodies (mAbs) to DENV, we showed that most antibodies that reacted to DENV envelope protein also reacted to ZIKV. Antibodies to linear epitopes, including the immunodominant fusion-loop epitope, were able to bind ZIKV but were unable to neutralize the virus and instead promoted ADE. Our data indicate that immunity to DENV might drive greater ZIKV replication and have clear implications for disease pathogenesis and future vaccine programs for ZIKV and DENV.

Piyada Supasa - One of the best experts on this subject based on the ideXlab platform.

  • dengue virus sero cross reactivity drives Antibody Dependent Enhancement of infection with zika virus
    Nature Immunology, 2016
    Co-Authors: Wanwisa Dejnirattisai, Giovanna Barbaspaeth, Alexander Rouvinski, Anavaj Sakuntabhai, Thaneeya Duangchinda, Piyada Supasa, Wiyada Wongwiwat, Vanmai Caolormeau
    Abstract:

    Infection with Zika virus has occurred in areas previously exposed to dengue virus, a closely related flavivirus. Screaton and colleagues find that monoclonal antibodies to dengue virus cross-react with Zika virus and enhance infection.

  • dengue virus sero cross reactivity drives Antibody Dependent Enhancement of infection with zika virus
    Nature Immunology, 2016
    Co-Authors: Wanwisa Dejnirattisai, Giovanna Barbaspaeth, Alexander Rouvinski, Anavaj Sakuntabhai, Thaneeya Duangchinda, Piyada Supasa, Wiyada Wongwiwat, Vanmai Caolormeau
    Abstract:

    Zika virus (ZIKV) was discovered in 1947 and was thought to lead to relatively mild disease. The recent explosive outbreak of ZIKV in South America has led to widespread concern, with reports of neurological sequelae ranging from Guillain Barre syndrome to microcephaly. ZIKV infection has occurred in areas previously exposed to dengue virus (DENV), a flavivirus closely related to ZIKV. Here we investigated the serological cross-reaction between the two viruses. Plasma immune to DENV showed substantial cross-reaction to ZIKV and was able to drive Antibody-Dependent Enhancement (ADE) of ZIKV infection. Using a panel of human monoclonal antibodies (mAbs) to DENV, we showed that most antibodies that reacted to DENV envelope protein also reacted to ZIKV. Antibodies to linear epitopes, including the immunodominant fusion-loop epitope, were able to bind ZIKV but were unable to neutralize the virus and instead promoted ADE. Our data indicate that immunity to DENV might drive greater ZIKV replication and have clear implications for disease pathogenesis and future vaccine programs for ZIKV and DENV.

Giovanna Barbaspaeth - One of the best experts on this subject based on the ideXlab platform.

  • dengue virus sero cross reactivity drives Antibody Dependent Enhancement of infection with zika virus
    Nature Immunology, 2016
    Co-Authors: Wanwisa Dejnirattisai, Giovanna Barbaspaeth, Alexander Rouvinski, Anavaj Sakuntabhai, Thaneeya Duangchinda, Piyada Supasa, Wiyada Wongwiwat, Vanmai Caolormeau
    Abstract:

    Infection with Zika virus has occurred in areas previously exposed to dengue virus, a closely related flavivirus. Screaton and colleagues find that monoclonal antibodies to dengue virus cross-react with Zika virus and enhance infection.

  • dengue virus sero cross reactivity drives Antibody Dependent Enhancement of infection with zika virus
    Nature Immunology, 2016
    Co-Authors: Wanwisa Dejnirattisai, Giovanna Barbaspaeth, Alexander Rouvinski, Anavaj Sakuntabhai, Thaneeya Duangchinda, Piyada Supasa, Wiyada Wongwiwat, Vanmai Caolormeau
    Abstract:

    Zika virus (ZIKV) was discovered in 1947 and was thought to lead to relatively mild disease. The recent explosive outbreak of ZIKV in South America has led to widespread concern, with reports of neurological sequelae ranging from Guillain Barre syndrome to microcephaly. ZIKV infection has occurred in areas previously exposed to dengue virus (DENV), a flavivirus closely related to ZIKV. Here we investigated the serological cross-reaction between the two viruses. Plasma immune to DENV showed substantial cross-reaction to ZIKV and was able to drive Antibody-Dependent Enhancement (ADE) of ZIKV infection. Using a panel of human monoclonal antibodies (mAbs) to DENV, we showed that most antibodies that reacted to DENV envelope protein also reacted to ZIKV. Antibodies to linear epitopes, including the immunodominant fusion-loop epitope, were able to bind ZIKV but were unable to neutralize the virus and instead promoted ADE. Our data indicate that immunity to DENV might drive greater ZIKV replication and have clear implications for disease pathogenesis and future vaccine programs for ZIKV and DENV.

Wiyada Wongwiwat - One of the best experts on this subject based on the ideXlab platform.

  • a protective zika virus e dimer based subunit vaccine engineered to abrogate Antibody Dependent Enhancement of dengue infection
    Nature Immunology, 2019
    Co-Authors: Jose Sloncampos, Wanwisa Dejnirattisai, Wiyada Wongwiwat, Bw Jagger, La Durnell, Cesar Lopezcamacho, Emma S Winkler, Rita E Chen, Arturo Reyessandoval
    Abstract:

    Infections with dengue virus (DENV) and Zika virus (ZIKV) can induce cross-reactive Antibody responses. Two immunodominant epitopes-one to precursor membrane protein and one to the fusion loop epitope on envelope (E) protein-are recognized by cross-reactive antibodies1-3 that are not only poorly neutralizing, but can also promote increased viral replication and disease severity via Fcγ receptor-mediated infection of myeloid cells-a process termed Antibody-Dependent Enhancement (ADE)1,4,5. ADE is a significant concern for both ZIKV and DENV vaccines as the induction of poorly neutralizing cross-reactive antibodies may prime an individual for ADE on natural infection. In this report, we describe the design and production of covalently stabilized ZIKV E dimers, which lack precursor membrane protein and do not expose the immunodominant fusion loop epitope. Immunization of mice with ZIKV E dimers induces dimer-specific antibodies, which protect against ZIKV challenge during pregnancy. Importantly, the ZIKV E-dimer-induced response does not cross-react with DENV or induce ADE of DENV infection.

  • dengue virus sero cross reactivity drives Antibody Dependent Enhancement of infection with zika virus
    Nature Immunology, 2016
    Co-Authors: Wanwisa Dejnirattisai, Giovanna Barbaspaeth, Alexander Rouvinski, Anavaj Sakuntabhai, Thaneeya Duangchinda, Piyada Supasa, Wiyada Wongwiwat, Vanmai Caolormeau
    Abstract:

    Infection with Zika virus has occurred in areas previously exposed to dengue virus, a closely related flavivirus. Screaton and colleagues find that monoclonal antibodies to dengue virus cross-react with Zika virus and enhance infection.

  • dengue virus sero cross reactivity drives Antibody Dependent Enhancement of infection with zika virus
    Nature Immunology, 2016
    Co-Authors: Wanwisa Dejnirattisai, Giovanna Barbaspaeth, Alexander Rouvinski, Anavaj Sakuntabhai, Thaneeya Duangchinda, Piyada Supasa, Wiyada Wongwiwat, Vanmai Caolormeau
    Abstract:

    Zika virus (ZIKV) was discovered in 1947 and was thought to lead to relatively mild disease. The recent explosive outbreak of ZIKV in South America has led to widespread concern, with reports of neurological sequelae ranging from Guillain Barre syndrome to microcephaly. ZIKV infection has occurred in areas previously exposed to dengue virus (DENV), a flavivirus closely related to ZIKV. Here we investigated the serological cross-reaction between the two viruses. Plasma immune to DENV showed substantial cross-reaction to ZIKV and was able to drive Antibody-Dependent Enhancement (ADE) of ZIKV infection. Using a panel of human monoclonal antibodies (mAbs) to DENV, we showed that most antibodies that reacted to DENV envelope protein also reacted to ZIKV. Antibodies to linear epitopes, including the immunodominant fusion-loop epitope, were able to bind ZIKV but were unable to neutralize the virus and instead promoted ADE. Our data indicate that immunity to DENV might drive greater ZIKV replication and have clear implications for disease pathogenesis and future vaccine programs for ZIKV and DENV.